Clinical Trials
12 trialsNCT05243550 2026-05-11
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT04165317 2026-01-22
CREST
Pfizer
Phase 3 Active not recruiting
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT02773849 2024-07-29
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
Phase 3 Completed
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated